These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 1320552)

  • 1. Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
    Warwick GL; Packard CJ; Murray L; Grierson D; Stewart JP; Shepherd J; Boulton-Jones JM
    Clin Sci (Lond); 1992 Jun; 82(6):701-8. PubMed ID: 1320552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
    Rabelink AJ; Hené RJ; Erkelens DW; Joles JA; Koomans HA
    Lancet; 1988 Dec; 2(8624):1335-8. PubMed ID: 2904053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
    Bredie SJ; Westerveld HT; Knipscheer HC; de Bruin TW; Kastelein JJ; Stalenhoef AF
    Neth J Med; 1996 Aug; 49(2):59-67. PubMed ID: 8824106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF; Stewart G; Bedford D; Stewart JP; Rogers E; Shepherd J; Packard CJ; Caslake MJ
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia.
    Schulzeck P; Bojanovski M; Jochim A; Canzler H; Bojanovski D
    Lancet; 1988 Mar; 1(8586):611-3. PubMed ID: 2894548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome.
    Wanner C; Böhler J; Eckardt HG; Wieland H; Schollmeyer P
    Clin Nephrol; 1994 Mar; 41(3):138-43. PubMed ID: 8187355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(2):247-57. PubMed ID: 2736571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term treatment with simvastatin on plasma lipids and lipoproteins in patients with primary hypercholesterolemia.
    Thiery J; Creutzfeldt C; Creutzfeldt W; Walli AK; Seidel D
    Klin Wochenschr; 1990 Aug; 68(16):814-22. PubMed ID: 2214604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans--in vitro and in vivo studies.
    Vitols S; Angelin B; Juliusson G
    Lipids; 1997 Mar; 32(3):255-62. PubMed ID: 9076662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
    Watts GF; Cummings MH; Umpleby M; Quiney JR; Naoumova R; Thompson GR; Sönksen PH
    Eur J Clin Invest; 1995 Aug; 25(8):559-67. PubMed ID: 7589011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers.
    Malmendier CL; Lontie JF; Delcroix C; Magot T
    Atherosclerosis; 1989 Dec; 80(2):101-9. PubMed ID: 2610723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome.
    Stenvinkel P; Berglund L; Ericsson S; Alvestrand A; Angelin B; Eriksson M
    Eur J Clin Invest; 1997 Feb; 27(2):169-77. PubMed ID: 9061312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
    Bredie SJ; de Bruin TW; Demacker PN; Kastelein JJ; Stalenhoef AF
    Am J Cardiol; 1995 Feb; 75(5):348-53. PubMed ID: 7856526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.
    Bard JM; Luc G; Douste-Blazy P; Drouin P; Ziegler O; Jacotot B; Dachet C; De Gennes JL; Fruchart JC
    Eur J Clin Pharmacol; 1989; 37(6):545-50. PubMed ID: 2693115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion.
    Cabezas MC; de Bruin TW; Kock LA; Kortlandt W; Van Linde-Sibenius Trip M; Jansen H; Erkelens DW
    Metabolism; 1993 Apr; 42(4):497-503. PubMed ID: 8487674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.
    Mol MJ; Stuyt PM; Demacker PN; Stalenhoef AF
    Neth J Med; 1990 Apr; 36(3-4):182-90. PubMed ID: 2355995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in the guinea pig: atorvastatin versus simvastatin.
    Conde K; Pineda G; Newton RS; Fernandez ML
    Biochem Pharmacol; 1999 Oct; 58(7):1209-19. PubMed ID: 10484079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects.
    Watts GF; Naoumova RP; Kelly JM; Riches FM; Croft KD; Thompson GR
    Am J Physiol; 1997 Sep; 273(3 Pt 1):E462-70. PubMed ID: 9316434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.